METHOD FOR PRODUCING LEISHMANIA RECOMBINANT PROTEINS AND USE IN A DIAGNOSTIC KIT AND VACCINE AGAINST LEISHMANIASES

• Main Authors: BARTHOLOMEU, DANIELLA CASTANHEIRA, SILVA, ANA LUIZA TEIXEIRA, BUENO, LILIAN LACERDA, GOMES, MATHEUS DE SOUZA, FUJIWARA, RICARDO TOSHIO, SOUZA, DANIEL MENEZES
• Format: Patent
• Language: English; French; Portuguese
• Published: 19.06.2014
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

The present invention relates to the use of recombinant HSP 83-1, MAPK and MAPK3 antigens, proteins present in protozoa of the Leishmania genus, for producing vaccines and a leishmaniasis diagnostic kits for humans and/or dogs. These antigens were selected by bioinformatics analysis involving immunoproteomic and phylogenetic algorithms. The ELISA reaction with anti-HSP 83-1, anti-MAPK and anti-MAPK3 antibodies could correctly identify non-infected and infected dogs. The results obtained were validated by reference diagnostic assays for canine visceral leishmaniasis (CVL) (EIE-LVC Bio-Manguinhos® kit). La présente invention concerne l'utilisation des antigènes recombinants HSP 83-1, MAPK et MAPK3, protéines présentes dans des protozoaires du genre Leishmania, afin de produire des vaccins et un kit de diagnostic contre les leishmanioses pour les êtres humains et/ou les chiens. Ces antigènes ont été sélectionnés au moyen d'une analyse bioinformatique faisant intervenir des algorithmes d'immunoprotéomique et de phylogénie. La réaction ELISA avec anticorps anti-HSP 83-1, anti-MAPK et anti-MAPK3 a permis d'identifier correctement les chiens non infectés et les chiens infectés. Les résultats obtenus ont été validés par des tests de référence pour diagnostic de leishmaniose viscérale canine (LVC) (kit EIE-LVC - Bio- Manguinhos®). A presente invenção se refere ao uso dos antígenos recombinantes HSP 83-1, MAPK e MAPK3, proteínas presentes em protozoários do gênero Leishmania, na produção de vacinas e kit diagnóstico contra leishmanioses para seres humanos e/ou cães. Esses antígenos foram selecionados por meio de análise de bioinformática, envolvendo algoritmos de imunoproteômica e filogenia. A reação de ELISA com anticorpos anti-HSP 83-1, anti-MAPK e anti- MAPK3 permitiu identificar corretamente os cães não infectados e os cães infectados. Os resultados obtidos foram validados por testes de referência para diagnóstico de Leishmaniose Visceral Canina (LVC) (Kit EIE-LVC - Bio- Manguinhos®).